RxDoctor Payments Data

Consonya Rogers

Psychiatric/Mental Health · Monroe, LANPI 1962722785

Payments from drug & device makers

$575in general payments, 2019–2025

Across 20 payments — averaging $28.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$295
  • Otsuka America Pharmaceutical, Inc.$143
  • Corium, LLC$26
  • Vanda Pharmaceuticals Inc.$25
  • Alkermes, Inc.$20
  • Takeda Pharmaceuticals U.S.A., Inc.$18
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$575100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$575 in reported general payments places this provider in the 30th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Medicare billing

Part B allowed, 2024
$11,144
Medicare patients
41
Services billed
171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole24$52,279
VraylarCariprazine Hcl18$24,720
NamzaricMemantine Hcl/Donepezil Hcl13$11,476
TrintellixVortioxetine Hydrobromide21$9,711
VyvanseLisdexamfetamine Dimesylate11$4,194
Trazodone Hcl174$2,765
Aripiprazole76$2,237
Bupropion XlBupropion Hcl112$2,103
Ziprasidone Hcl46$1,901
Duloxetine Hcl60$1,700
Venlafaxine Hcl ErVenlafaxine Hcl51$1,384
Quetiapine Fumarate72$1,232
Clonazepam296$1,155
Doxepin Hcl18$1,076
Buspirone Hcl56$871

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$143$52,27924 claims
AbbVieVraylar, Namzaric$295$36,19531 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$18$13,90532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →